Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
Key Points
Key Points
- This guideline focuses on patients with advanced, recurrent, or metastatic prostate cancer and noncastrate testosterone levels whose disease is not yet castration-resistant, including those with biochemical recurrence only.
- The future of noncastrate advanced, recurrent, or metastatic prostate cancer care is predicted to include highly personalized treatment plans based on advanced genetic testing, next generation imaging, and the availability of highly predictive biomarkers.
- This targeted update is driven by results from recent Phase III clinical trials (ARASENS, PEACE-1, ENZAMET, and ARCHES) and two recent meta-analyses.
Treatment
...Treatment...
...I...
...1.0(Updated) Docetaxel, abiraterone, enz...
...ANDROGEN DE...
...commendation 1.1(Updated) For patients with met...
...mendation 1.11(New) For patients wi...
...endation 1.15(New) For patients with d...
...ecommendation 1.16(New) The recommen...
...tion 1.2(Updated) For patients with lo...
...1.3(Updated) For patients with metastatic noncast...
...ADT PLUS ABI...
...dation 1.4For patients with high-risk de novo...
...mmendation 1.5For patients with low-...
...1.6The recommended regimen for patients wit...
...ADT PLUS ENZ...
...ecommendation 1.7(Updated) ADT plus enzalutami...
...ation 1.8(Updated) The recommended regimen fo...
...ADT PLUS APAL...
...endation 1.9ADT plus apalutamide shoul...
...mmendation 1.95(Updated) The recommended reg...
...Com...
...ecommendation 2.1ADT plus abiraterone and...
...commendation 2.2In resource-constrained s...
...Early An...
...ation 3.1Early (immediate) ADT may be offered...
...I...
...mmendation 4.1Intermittent therapy may be...
...l Management of Noncastrate Metastatic Prostate...